Previous 10 | Next 10 |
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium PR Newswire - "LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy" will present the most recent and robust data on LSD in...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year, and despite the abundance of antianxiety med...
MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer PR Newswire - Dr. Lilienthal brings over 20 years of global biopharmaceutical experience, leading the development and commercialization of innovative medicines across multiple therapeutic areas includ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelic medical treatments and therapies are getting a growing amount of attention from investors. Magic mushroom ingredient psilocybin has shown promise in treating a number of mental health disorders and addictio...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2022 – Depression and anxiety affect millions around the world and the venom of a toad is the latest psychedelic compound being used as an alternative treat...
MindMed Reports Proposed Change in Auditor for 2022 Fiscal Year Canada NewsWire NEW YORK , March 29, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company develo...
Mind Medicine (MindMed) Inc. (MNMD) Q4 2021 Earnings Conference Call March 28, 2022 08:30 ET Company Participants Rob Barrow - Chief Executive Officer Dan Karlin - Chief Medical Officer Miri Halperin Wernli - Executive President Conference Call Participants Patrick Trucchio - H.C. Wainwright ...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) reported its financial results for the full year ended December 31, 2021 . MindMed has no revenue at this time but did report that the net loss for the year was $92.3 million , compared to $33.7 milli...
Mind Medicine press release (NASDAQ:MNMD): FY GAAP EPS of -$0.23 in-line. Cash of $133.5M. The company believes its available cash and cash equivalents will be sufficient to meet its operating requirements beyond its key development milestones in 2023 and into 2024. CEO comment: "We expect 20...
MindMed Reports Full Year 2021 Financial Results and Business Highlights Canada NewsWire - FDA cleared MindMed's Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 - - Progressed development programs for all three lead...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corpo...
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...